Piper Sandler analyst Edward Tenthoff maintains $RAPT Therapeutics (RAPT.US)$ with a hold rating, and adjusts the target price from $7.97 to $2.
According to TipRanks data, the analyst has a success rate of 32.2% and a total average return of -12.6% over the past year.
Furthermore, according to the comprehensive report, the opinions of $RAPT Therapeutics (RAPT.US)$'s main analysts recently are as follows:
The decision to halt Rapt Therapeutics' zelnecirnon program was influenced by feedback from the FDA, which indicated challenges in conclusively disproving drug-induced liver failure. The discontinuation, paired with the current ambiguity surrounding the development of next-generation compounds and the potential need for additional capital, positions Rapt as a company requiring further evidence before gaining confidence in its outlook.
The FDA's request for definitive evidence concerning liver SAE was more conservative than experts anticipated. This was noted alongside the positive indications of efficacy from the Phase 2b trials, which augur well for the development of next-generation compounds. Anticipation is high for forthcoming data to evaluate the potential.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
派傑投資分析師Edward Tenthoff維持$RAPT Therapeutics (RAPT.US)$持有評級，並將目標價從7.97美元下調至2美元。
根據TipRanks數據顯示，該分析師近一年總勝率為32.2%，總平均回報率為-12.6%。
此外，綜合報道，$RAPT Therapeutics (RAPT.US)$近期主要分析師觀點如下：
終止rapt therapeutics的zelnecirnon項目的決定受到FDA反饋的影響，FDA表示在確定地證僞藥物誘導的肝功能衰竭方面存在挑戰。停止該項目，加上目前關於下一代化合物開發的模糊性和可能需要額外資本的問題，使Rapt公司成爲需要進一步證據才能對其前景充滿信懇智能的公司。
FDA對有關肝SAE的確鑿證據的要求比專家預期的更保守。這一點注意到了階段20億試驗中的療效積極跡象，這爲下一代化合物的開發提供了良好的前景。人們懷着期待之情，期待着即將公佈的數據，以評估潛在性。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
